Last reviewed · How we verify
Ocular hypertension
Approved treatments
- Alphagan · Senju Pharmaceutical Co., Ltd
- Trusopt · Merck & Co.
Trusopt works by inhibiting the enzyme carbonic anhydrase 2, which is involved in the production of aqueous humor in the eye. - Betagan · AbbVie
- Alphagan · Senju Pharmaceutical Co., Ltd
- Betaxon · Alcon Pharms Ltd
- Taxol · Pfizer
Taxol works by binding to tubulin and preventing the formation of microtubules, which are essential for cell division. - Azopt · Alcon Research
- Mannitol · Baxter
Osmotic diuretic that elevates glomerular filtrate osmolarity to inhibit tubular water reabsorption. - Bentos
Bentos works by reducing the production of fluid in the eye, thereby lowering intraocular pressure. - Isobide · Alvogen Korea
- Optipranolol · Bausch Health
- Azopt · Novartis
Brinzolamide reduces intraocular pressure by inhibiting carbonic anhydrase II, decreasing aqueous humor secretion. - Xalatan · Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
- Xalatan · Thea Pharma
Xalatan works by increasing the outflow of fluid from the eye, reducing pressure. - Travatan
Travatan works by increasing the outflow of fluid from the eye to reduce pressure. - Lumigan
Lumigan works by increasing the outflow of fluid from the eye to reduce pressure. - Taxol · Pfizer
- Ocupress
- Isobide · Novartis
- Salagen
- Vyzulta · Bausch Health
Vyzulta works by activating the Prostaglandin F2-alpha receptor, which increases the outflow of aqueous humor from the eye, thereby reducing intraocular pressure. - Aridol Kit · Baxter
Mannitol works by drawing water into the bloodstream from surrounding tissues, increasing urine production and reducing fluid accumulation in the body. - Rhopressa · Alcon Labs Inc
Netarsudil reduces intraocular pressure by increasing aqueous humor outflow through the trabecular meshwork. - Betoptic · Novartis
Betaxolol works by blocking the beta-1 adrenergic receptor in the heart and eyes, reducing heart rate and pressure, and decreasing intraocular pressure. - Taxol · Pfizer
- Glanatec · Michael D. Straiko, MD
- Travatan · Alcon Research
- Abraxane · The First Affiliated Hospital with Nanjing Medical University
- Salagen · Alberta Health services
- Taxol · M.D. Anderson Cancer Center
Clinical guidelines
- FDA label — 1L
OSMITROL is indicated for the reduction of elevated intraocular pressure. - FDA label — 1L
OSMITROL is indicated for the reduction of elevated intraocular pressure. - FDA label — 1L
OSMITROL is indicated for the reduction of elevated intraocular pressure. - FDA label — 1L
OSMITROL is indicated for the reduction of elevated intraocular pressure.
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Ocular hypertension patent landscape — cliff calendar, originator estates, attackable patents
- Ocular hypertension treatment landscape brief
- Ocular hypertension treatment updates RSS
Frequently asked questions about Ocular hypertension
What drugs treat Ocular hypertension?
Tracked treatments include Alphagan, Trusopt, Betagan, Betaxon, Taxol, Azopt, Mannitol, Bentos.
What is the treatment for Ocular hypertension?
Standard treatment for Ocular hypertension includes Alphagan, Trusopt, Betagan, Betaxon, Taxol. See the treatment landscape page for first-line, second-line and salvage options.
What are the treatment guidelines for Ocular hypertension?
FDA label publishes guidelines for Ocular hypertension. 4 guideline references tracked.
Related
- Treatment landscape: Ocular hypertension patent cliff · Ocular hypertension CI report
- Treatment: Alphagan · Senju Pharmaceutical Co., Ltd
- Treatment: Trusopt · Merck & Co.
- Treatment: Betagan · AbbVie
- Treatment: Alphagan · Senju Pharmaceutical Co., Ltd
- Treatment: Betaxon · Alcon Pharms Ltd
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing